There is no single “best” IV infusion for rheumatoid arthritis. Five IV biologics are currently approved for RA, and each works through a different mechanism, follows a different schedule, and suits different clinical situations. The right choice depends on which medications you’ve already tried, how your body responds, and what your rheumatologist identifies as the best target in your specific case. Here’s what you need to know about each option and how they compare.
When IV Infusions Enter the Picture
IV biologics aren’t first-line treatment for RA. The 2021 American College of Rheumatology guidelines recommend starting with methotrexate, then maximizing that dose before escalating. If you’re on the highest tolerable dose of methotrexate and still not reaching your treatment target, adding a biologic or targeted synthetic drug is the recommended next step. Most of the IV infusions below are used alongside methotrexate rather than replacing it entirely.
The Five IV Options
Infliximab (Remicade)
Infliximab is a TNF blocker, meaning it neutralizes one of the key inflammatory proteins driving joint damage in RA. It’s given at weeks 0, 2, and 6 as a loading phase, then every 8 weeks after that. The dose is weight-based at 3 mg/kg and must be paired with methotrexate. TNF blockers as a class tend to work fast: many patients notice improvement in joint swelling and pain within 2 to 4 weeks, with continued gains over 3 to 6 months. In clinical trials, about 32% of patients on infliximab plus methotrexate achieved a 50% improvement in RA symptoms at one year, compared to 21% on methotrexate alone. Several biosimilar versions are available, which can significantly reduce cost.
Golimumab (Simponi Aria)
Golimumab is also a TNF blocker but follows a slightly different schedule: infusions at weeks 0 and 4, then every 8 weeks. The dose is 2 mg/kg. Because it targets the same pathway as infliximab, the onset and general efficacy profile are similar, though head-to-head data between the two is limited. One comparative analysis suggested potential differences in remission rates among TNF blockers, but the results weren’t statistically definitive. In practice, rheumatologists often choose between TNF blockers based on insurance coverage, dosing convenience, and individual tolerance.
Tocilizumab (Actemra)
Tocilizumab works differently from TNF blockers. It blocks a signaling molecule called interleukin-6 (IL-6), which drives inflammation, fatigue, and the elevated blood markers commonly seen in active RA. The IV dose is 8 mg/kg every 4 weeks, capped at 800 mg per infusion. Improvement typically appears within 4 to 8 weeks.
Tocilizumab requires more frequent lab monitoring than some other options. Your provider will check liver enzymes and white blood cell counts 4 to 8 weeks after starting treatment and every 3 months thereafter. Cholesterol levels also need to be assessed within the first couple of months and then every 6 months. If liver enzymes rise above certain thresholds, the dose may be cut in half or paused. If white blood cell counts drop too low, treatment is held until they recover. This doesn’t mean the drug is more dangerous overall, but it does mean more regular blood draws are part of the routine.
Abatacept (Orencia)
Abatacept takes a completely different approach. Instead of blocking an inflammatory protein directly, it prevents immune cells called T cells from becoming fully activated in the first place. By interrupting activation early in the inflammatory chain, it dials down the downstream cascade that causes joint swelling and damage. The IV dose is weight-tiered: 500 mg if you weigh under 60 kg, 750 mg for 60 to 100 kg, and 1,000 mg for over 100 kg. After an initial loading phase at weeks 0, 2, and 4, infusions settle into an every-4-weeks rhythm.
Abatacept is generally considered to have a gentler side effect profile, but the tradeoff is a slower onset. Responses typically take about 3 months to become noticeable. For patients who value a lower risk of certain side effects and can tolerate a longer wait for results, abatacept is often a strong candidate.
Rituximab (Rituxan)
Rituximab depletes a type of immune cell called B cells, which produce the antibodies that attack joint tissue in RA. The dosing schedule is distinctive: two 1,000 mg infusions given two weeks apart, forming one cycle. That cycle is repeated every 24 weeks (about 6 months), or sometimes longer depending on how you respond. This means far fewer total infusion visits per year compared to the other options.
The catch is that rituximab works slowly. Effects often don’t appear for up to 3 months after the infusion cycle. It’s also typically reserved for patients who haven’t responded adequately to at least one TNF blocker, making it more of a second- or third-line biologic rather than a first choice. Each infusion session is longer too. The first infusion takes about 4 hours and 15 minutes. Subsequent infusions can often be shortened to around 2 hours once your provider confirms you tolerate the drug well.
How Infusion Sessions Work
Regardless of which drug you receive, the basic experience is similar. You’ll sit in a clinic infusion chair while the medication is delivered through an IV line. Session length varies: tocilizumab and abatacept infusions typically run about 30 minutes to an hour, while rituximab’s first session stretches past 4 hours. Infliximab and golimumab usually fall somewhere in between at roughly 2 hours.
Before some infusions, particularly rituximab, you’ll receive pre-medications to reduce the chance of a reaction. This typically includes a steroid given through the IV, plus oral acetaminophen and an antihistamine taken 30 to 60 minutes beforehand. Infusion reactions, when they occur, usually involve symptoms like flushing, headache, or mild nausea. Serious reactions are uncommon but are the reason infusion centers monitor you during and after each session.
Infection Risk Across All Options
All IV biologics suppress part of the immune system, which means a higher risk of infections. In a large study tracking over 11,600 RA patients, about 5.9% experienced a serious infection during follow-up. That risk is real but relatively low, and it’s managed through screening before starting treatment (particularly for tuberculosis and hepatitis B), staying current on vaccinations, and monitoring for symptoms like persistent fever or cough between infusions.
How Rheumatologists Choose
Since no head-to-head trial has definitively crowned one IV biologic as superior, the decision is driven by several practical factors. If you’ve never been on a biologic before, a TNF blocker like infliximab or golimumab is a common starting point because they have the longest track record and the fastest onset. If TNF blockers haven’t worked or caused side effects, switching to a different mechanism like tocilizumab or abatacept is the standard approach. Rituximab is typically reserved for patients who’ve already failed a TNF blocker.
Insurance coverage plays a major role. Biosimilars for infliximab and rituximab have brought costs down considerably for those two drugs, sometimes making them the most financially accessible options. Dosing frequency also matters to patients: if you prefer fewer visits, rituximab’s twice-yearly cycle is appealing, while every-4-week infusions of tocilizumab or abatacept mean more frequent trips but shorter individual sessions.
Your other health conditions factor in as well. Tocilizumab’s effect on liver enzymes and cholesterol may make it less ideal if you already have elevated levels. Rituximab’s deep immune suppression of B cells may not suit someone with a history of recurring infections. And if you respond to a TNF blocker but prefer fewer needles overall, the every-8-week schedule of infliximab or golimumab offers a middle ground.
The “best” infusion is ultimately the one that controls your RA with the fewest side effects and fits into your life. That answer is different for every patient, and it often takes a conversation with your rheumatologist, weighing your disease activity, treatment history, and personal preferences, to land on the right fit.